Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi‐centre, randomized, single‐blind comparison trial
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Introduction The aim of this trial was to compare lorazepam with non‐benzodiazepine medications such as pregabalin and tiapride in the treatment of alcohol withdrawal syndrome (AWS). These drugs were chosen for their inhibitorial effects on the hypersecretion of neurotransmitters usually observed in AWS. Craving reduction and improvement of psychiatric symptoms were the secondary end‐points. Methods One hundred and ninety subjects affected by current alcohol dependence were considered consecutively: 111 were enrolled and divided into three groups of 37 subjects each. Within a treatment duration of 14 days, medication was given up to the following maximum doses (pregabalin 450 mg/day; tiapride 800 mg/day; lorazepam 10 mg/day). Withdrawal (CIWA‐Ar), craving [visual analogue scale (VAS); Obsessive and Compulsive Drinking Scale (OCDS)], psychiatric symptoms [Symptom Check List 90 Revised (SCL‐90‐R)] and quality of life (QL‐index) rating scales were applied. Results On the CIWA‐Ar score, all the groups showed a significant reduction between times (P < 0.001) with a higher reduction for the pregabalin group (P < 0.01) on items regarding headache and orientation. Retention in treatment was lower in the tiapride group (P < 0.05), while the number of subjects remaining alcohol free was higher in the pregabalin group (P < 0.05). Significant reduction between baseline and the end of the treatment was found in all the groups at the OCDS and the VAS for craving, at the SCL‐90‐R and QL‐index (P < 0.001). Discussion All the medications in the trial showed evidence of safety and efficacy in the treatment of uncomplicated forms of AWS, with some particular differences. The efficacy of pregabalin was superior to that of tiapride, used largely in research trials and, for some measures, to that of the ‘gold standard’, lorazepam. Accordingly, pregabalin may be considered as a potentially useful new drug for treatment of AWS, deserving further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SULLIVAN, J. T., SYKORA, K., SCHNEIDERMAN, J., NARANJO, C. A., & SELLERS, E. M. (1989) · British Journal of Addiction · doi:10.1111/j.1360-0443.1989.tb00737.x · Cited by 1,988 · cited 3×
“CIWA-Ar [20,21] and the Visual Analogue Scale for Craving (VASc) [63] were administered once a day (immediately before the first daily administration of the drug) on days 1, 2, 3, 4, 5, 6, 7 and 14.”
BackgroundMethodSaitz, R. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp042262 · Cited by 599 · cited 1×
“At present, benzodiazepines (BZs) are the drugs of choice in the treatment of AWS [25,26] as they have proved their efficacy in ameliorating symptoms and decreasing the risk of seizures and delirium tremens [27].”
BackgroundManagement of Drug and Alcohol Withdrawal
Kosten, T. R., & O'Connor, P. G. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020617 · Cited by 563
Mayo-Smith, M. F. (1997) · JAMA · doi:10.1001/jama.278.2.144 · Cited by 434
Drug therapy for alcohol dependence
Swift, R. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905133401907 · Cited by 255
Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.7.848 · Cited by 176 · cited 1×
“This profile is in contrast to the occurrence of discontinuation symptoms and rebound anxiety when therapeutic doses of benzodiazepines are discontinued abruptly after some weeks of therapy [71,72].”
ResultClorazepate and lorazepam: clinical improvement and rebound anxiety
(1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.3.312 · Cited by 50 · cited 1×
“This profile is in contrast to the occurrence of discontinuation symptoms and rebound anxiety when therapeutic doses of benzodiazepines are discontinued abruptly after some weeks of therapy [71,72].”
ResultMorgan, P. T., & Malison, R. T. (2008) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990802308221 · Cited by 32
Cited by
Gabapentin for the treatment of alcohol use disorder
Mason, B. J., Quello, S., & Shadan, F. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1417383 · Cited by 104
“Pregabalin (200–450 mg/d) has shown efficacy for treating uncomplicated alcohol withdrawal and related negative affective symptoms in one open-label study (N = 40)[83] and one multi-center, randomized, single-blind comparison trial with tiapride and lorazepam (N = 111) [84], as well as in a preclinical study of alcoho…”
Carrus, D., & Schifano, F. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318272864d · Cited by 49
Faustmann, T. J., Paschali, M., Kojda, G., Schilbach, L., & Kamp, D. (2025) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2029-6387 · Cited by 4
Metadata
- Authors
- Martinotti, G., Di Nicola, M., Frustaci, A., Romanelli, R., Tedeschi, D., Guglielmo, R., Guerriero, L., Bruschi, A., De Filippis, R., Pozzi, G., Di Giannantonio, M., Bria, P., & Janiri, L.
- Venue
- Addiction
- Publisher
- Wiley
- Published
- 2010-01-11
- Volume
- 105
- Issue
- 2
- Pages
- 288-299
- ISSN
- 0965-2140 (ISSN-L)
- 1360-0443
- OpenAlex
- W1978434699
- Cited by
- 83
- References
- 8
- FWCI
- 5.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi‐centre, randomized, single‐blind comparison trial. https://app.cochat.ai/papers/10.1111/j.1360-0443.2009.02792.x
- The paper
- Martinotti, G., Di Nicola, M., Frustaci, A., Romanelli, R., Tedeschi, D., Guglielmo, R., Guerriero, L., Bruschi, A., De Filippis, R., Pozzi, G., Di Giannantonio, M., Bria, P., & Janiri, L. (2010). Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi‐centre, randomized, single‐blind comparison trial. Addiction. https://doi.org/10.1111/j.1360-0443.2009.02792.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.